FindTrial
Sign In

To assess the efficacy of mycophenolate mofetil in acquired dermatoses with dermal hyperpigmentation.

Efficacy of mycophenolate mofetil in acquired dermal macular hyperpigmentation: An open label pilot study

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2018/06/014650
Enrollment
25
Registered
2018-06-28
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Lichen planus pigmentosus/ Acquired dermal macular hyperpigmentation

Interventions

Intervention1: Mycophenolate mofetil: After appropriate investigations, mycophenolate mofetil shall be started per oral from 500 mg twice a day, and shall be gradually increased to 1 gram twice per da

Sponsors

None
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with a cliniopathological diagnosis of acquired dermal macular hyperpigmentation. 1. Age >18 years. 2. Consenting for inclusion in the study

Exclusion criteria

Exclusion criteria: 1. Age 2. Pregnancy/Lactation 3. Patients with severe hepatic, renal disease or dyslipidemia 4. Pre existing malignancy

Design outcomes

Primary

MeasureTime frame
To assess the efficacy of mycophenolate mofetil (MMF) in reducing the disease severity of acquired dermal macular hyperpigmentation (ADMH).Timepoint: 24 weeks of treatment followed by 12 weeks of follow-up—

Secondary

MeasureTime frame
1. To assess the efficacy of MMF in decreasing disease activity in ADMH 2. To assess the safety of MMF in disorders of ADMH. Timepoint: 24 weeks treatments followed by 12 weeks of follow-up.—

Countries

India

Contacts

Public ContactDr Sendhil M Kumaran

Postgraduate institute of medical education and research

drsen_2000@yahoo.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026